JOHNSON & JOHNSON (JNJ)
Johnson & Johnsons RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
Johnson & Johnsons RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
📈 **POSITIVE** • High confidence analysis (81%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business